Europe Supports Autoantibodies as Biomarkers for T1D
It was 2015—five years ago—that three organizations (BreakthroughT1D, the Endocrine Society and the American Diabetes Association) published a statement urging the adoption of a staging system of type 1 diabetes (T1D) that uses islet autoantibodies as biomarkers. (Biomarkers, in this sense, are indicators that a person is developing T1D but is still without symptoms.) It […]
In-Home Test Kits Make Screening Convenient and Easy
TrialNet—an international Breakthrough T1D-supported network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams dedicated to finding cures for type 1 diabetes (T1D)—has a new in-home test kit that makes screening far more easy and convenient. And FedEx will come pick it up, at no cost to you! If you have a relative with […]
Strengthening Type 1 Diabetes Science by Building Careers
Sometimes, the funding that Breakthrough T1D can provide for researchers is exactly the invitation they need to get into the field of type 1 diabetes (T1D) research. Other times, sustained grants are the critical boost that someone with more experience needs in order to branch out and establish his or her own lab. Creating and […]
Universal Screening for Type 1 Diabetes: Its Time has Come?
Universal screening for type 1 diabetes (T1D) is a priority for Breakthrough T1D, but the cost versus benefits remain unclear. Now, a large-scale population study in Bavaria, Germany, headed by Breakthrough T1D-funded Anette-Gabriele Ziegler, M.D., Ph.D., has a clue. The Fr1da study of nearly 100,000 children suggests that screening for autoantibodies—antibodies that are directed toward your […]
A Team in Boston Trying to Prevent Type 1 Diabetes
Breakthrough T1D is funding work on multiple ways to delay or prevent the onset of type 1 diabetes (T1D). This team thinks fat tissue may hold a key to this research. Kacey Prentice, Ph.D., works with other researchers in the Hotamisligil Lab at the Harvard T.H. Chan School of Public Health. There, she is helping […]
Can Two Viral Drugs Halt Type 1 Diabetes?
Scientists in Norway are seeking participants for a clinical trial to see if a course of anti-viral treatment may stop beta cell destruction. Pancreatic infection with some viruses, known as enteroviruses, are a likely candidate as one of the environmental causes of type 1 diabetes (T1D). The reason: Evidence of enteroviral infection has been found […]
FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention or delay of type 1 diabetes (T1D) in individuals at-risk of developing the disease. CD3 is a blood marker that helps to activate the immune cells—called T cells—which are thought to be responsible for the […]
ADA Scientific Sessions Recap—T1D Prevention Research: Jessica Dunne, Ph.D.
There was some really exciting T1D prevention research in day #3, and also screening for type 1 diabetes risk. Here is Jessica Dunne, Ph.D., senior director of the prevention portfolio, who gives a recap of day in T1D prevention research:
First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune therapy demonstrated a significant delay in the time to onset of type 1 diabetes (T1D) in high-risk relatives of people with the disease. A significant delay meaning 2+ years! This is the first ever study […]
Multiple Benefits of Screening For Beta Cell Autoimmunity in Children
Learn more about Breakthrough T1D’s prevention research and the benefits of early detection for type 1 diabetes (T1D).
